Editor's Choice: Recently, in order to improve the effect of pancreatic cancer immunotherapy, the team of Professor Yang Yinmo and Director Tian Xiaodong, President of Peking University First Hospital and Department of Hepatobiliary and Pancreatic Surgery, and Professor Nie Guangjun and Professor Zhu Motao's research group of the National Center for Nanoscience have cooperated in-depth to synthesize a new nano-hybrid bacterial vesicle system through nano-bioengineering technology, significantly enhancing the targeting ability while reducing adverse reactions, showing good application prospects.
Recently, in order to improve the effect of pancreatic cancer immunotherapy, Professor Yang Yinmo and Director Tian Xiaodong, President of Peking University First Hospital, Department of Hepatobiliary and Pancreatic Surgery, and Professor Nie Guangjun and Professor Zhu Motao's research group of the National Center for Nanoscience have cooperated in-depth to synthesize a novel nano-hybrid bacterial vesicle system through nano-bioengineering technology, significantly enhancing the targeting ability and reducing adverse reactions, showing good application prospects. The study "Commensal bacterial hybrid nanovesicles improve immune checkpoint therapy in pancreatic cancer through immune and metabolic reprogramming" was published online in the journal Nano Today (IF=17.4).
Paper publication cover
In recent years, with the development and application of chemotherapy, targeted and immunotherapy drugs, the long-term survival rate of cancer patients has been significantly improved. Among them, immunotherapy makes the body produce tumor-specific immune response through active and passive methods, achieves the purpose of inhibiting and killing tumors with high efficiency, specificity and persistence, and has made remarkable progress in the treatment of a variety of tumors. However, pancreatic cancer has special characteristics, the response rate of immunotherapy is generally low, and the treatment effect is significantly lower than that of other tumors, mainly because pancreatic cancer cells have low autoimmunogenicity and are not easy to be recognized by immune cells, followed by fewer immune effector cells with tumor-killing effect in the tumor immune microenvironment, making it difficult for immunotherapy to play a role. Therefore, pancreatic cancer is called an immune "cold" tumor.
Recent studies have found that symbiotic microorganisms in the human body play an important role in regulating host immune homeostasis and tumor immune microenvironment, and specific gut microorganisms can significantly improve the response of tumors to immunotherapy, thereby improving the effect of immunotherapy and improving the prognosis of patients.
Screenshot of the paper
Based on the above background, the team of Yang Yinmo and Tian Xiaodong cooperated deeply with Nie Guangjun and Zhu Motao's research groups to design a nano-heterozygous vesicle system synthesized by specific intestinal microbial functional components for pancreatic cancer, which can reprogram the immune and metabolic microenvironment of pancreatic cancer, increase the number and activity of immune cells in pancreatic cancer tissues, thereby improving the effect of pancreatic cancer immunotherapy, and transforming "cold" tumors into "hot" tumors of immunotherapy.
The above-mentioned nano-hybrid bacterial vesicle system synthesized by nano-bioengineering technology removes virulence factors such as pyrogens from microorganisms while retaining the functional components of intestinal bacteria immunomodulation, overcomes the adverse reactions such as abdominal discomfort, vomiting, fever and diarrhea caused by direct transplantation of live bacteria, and also avoids the risk of multi-drug resistance or pathogenic microorganism transmission. The treatment system is administered intravenously, which has superior targeting ability for tumors and their draining lymphoid organs, and shows good application prospects in inducing innate immune activation, dendritic cell maturation, tumor antigen presentation, and tumor microenvironment reprogramming.
Group photo of the team
The research relies on the National Key Research and Development Program, the National Natural Science Foundation of China, the Beijing Municipal Natural Science Foundation and other projects, with the support and guidance of Professor Wang Hai, Researcher Meng Xian and Associate Professor Chen Lin of the National Center for Nanoscience, and Dr. Liu Guangnian and Dr. Huang Wenping have made important contributions to the specific implementation of the project.
The team of Yang Yinmo and Tian Xiaodong has long-term cooperation with the National Center for Nanoscience, and has achieved many achievements in the field of nanomedicine and its translational medicine, and has published many papers in journals such as NanoToday and ACSNano, which have attracted widespread attention.
Source: Peking University News Network
Disclaimer: Kanga is committed to the dissemination of health knowledge, the content is edited according to public materials, and the copyright belongs to the original author; If there is any infringement, please leave a message online to delete. Articles are intended to introduce advances in health science and are not intended as a treatment option; If you need accurate health guidance, please go to a regular hospital.